Antineoplastics (CDK4/6 inhibitors)
- Block cell-cycle progression through CDK4/6
- Core therapy for HR+/HER2− breast cancer
- Palbociclib/ribociclib/abemaciclib
- Neutropenia prominent with palbo/ribo
- Diarrhea prominent with abemaciclib
- Ribociclib: QT + liver monitoring
- Usually combined with endocrine therapy
Class at a glance
- Block cell-cycle progression through CDK4/6
Safety / monitoring
- Ribociclib: QT + liver monitoring
Clinical role
- Core therapy for HR+/HER2− breast cancer
- Palbociclib/ribociclib/abemaciclib
Members / distinctions
- Neutropenia prominent with palbo/ribo
- Diarrhea prominent with abemaciclib
- Usually combined with endocrine therapy
Self-check
- What is the main pharmacologic action of Antineoplastics (CDK4/6 inhibitors)?
Block cell-cycle progression through CDK4/6.
- What clinically distinguishes Ribociclib within Antineoplastics (CDK4/6 inhibitors)?
QT + liver monitoring.
Drugs in this class (3)
All drug classes · Open the interactive console ↗
